tbuckley/cabot-search huggingface dataset:
Effects of acute hyperglycemia on myocardial glycolytic activity in humans.
Authors: J A Wisneski, W C Stanley, R A Neese, E W Gertz
Journal: Journal of Clinical Investigation (1990)

The effects of hyperglycemia on myocardial glucose metabolism were investigated in seven healthy male subjects (age 24 +/- 4 yr). [6-14C]Glucose and [U-13C]lactate were infused as tracers. Circulating glucose was elevated to two hyperglycemic levels using a clamp technique for 1 h at each level. The mean arterial glucose concentration was 4.95 +/- 0.29 (control), 8.33 +/- 0.31 and 10.84 +/- 0.60 mumols/ml, respectively. Glucose extraction increased significantly from control (0.15 +/- 0.13 mumols/ml) during each level of the glucose clamp (0.28 +/- 0.12, P less than 0.02, and 0.54 +/- 0.14 mumols/ml, P less than 0.005, respectively). Myocardial production of 14CO2 showed that during control 9 +/- 10% of exogenous glucose was oxidized immediately upon extraction. Despite a significant increase in the amount of exogenous glucose oxidized with level II hyperglycemia, it represented only 32 +/- 10% of the glucose extracted. [13C]Lactate analysis showed that the myocardium was releasing lactate; during control 40 +/- 30% of this lactate was derived from exogenous glucose and during hyperglycemia this value increased to 97 +/- 37% (P less than 0.005). Thus, these data show that during short-term hyperglycemia, myocardial glucose extraction is enhanced. However, despite increases in exogenous glucose oxidation and the contribution of exogenous glucose to lactate release, the majority of the extracted glucose (i.e., 57%) is probably stored as glycogen.
Postmortem Examination-Reply
Authors: Stanley Burrows
Journal: JAMA (1976)

<h3>In Reply.—</h3> My review of autopsy findings was an attempt to evaluate their importance relative to the effort involved and should not be interpreted as a general deprecation of postmortem studies. Several references noted in my article stressed the value of the autopsy for medical progress and the quality control of medical practice, but provided little or no concrete data to support these views. Every medical specialty can benefit from at least occasionally questioning its work to determine results of selected procedures. As noted by Dr Swank, a high autopsy percentage by itself may not be a valid criterion of quality. All of the autopsy findings in each patient were analyzed both on the basis of agreement with the clinical diagnoses and clinical importance of any discrepancies. Although a panel of clinicians may have been helpful in the correlation of autopsy findings and clinical diagnoses, I believe that a pathologist
Abstract 3162: MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
Authors: Hailong Zhang, Lubing Gu, Jiansha Li, Jing He, Muxiang Zhou
Journal: Cancer Research (2010)

Abstract The MYCN gene plays a critical role in determining the clinical behavior of neuroblastoma. Genomic amplification occurs in high-risk subsets, but it remains unclear how MYCN expression is regulated in human neuroblastomas. Here, we report that the expression of MYCN is regulated by the oncoprotein MDM2 at the post-transcriptional level. Ectopic overexpression of MDM2 or an increase in the cytoplasmic levels of endogenous MDM2 by inhibition of PI3K/Akt activity enhanced both MYCN mRNA and protein expression. UV cross-linking and RNA-protein binding assays demonstrated that the C-terminal RING domain of MDM2 bound to AU-rich elements within the 3’-untranslated region (3’-UTR) of MYCN mRNA. Furthermore, gene transfection and reporter assay confirmed that MDM2 increased MYCN 3’-UTR-mediated mRNA stability and induced translation of reporter luciferase. Conversely, MDM2 silencing by specific siRNA rendered the MYCN mRNA unstable, reducing the abundant MYCN protein found in MYCN-overexpressing neuroblastoma cell lines, which are a consequence of gene amplification. Importantly, silencing of MDM2 in MYCN-amplified neuroblastoma cell lines resulted in a remarkable inhibition of cell growth and induction of cell death, through a p53-independent pathway. These results indicate that MDM2 plays a p53-independent role in regulating MYCN mRNA stabilization and protein translation, and suggest that MDM2-mediated MYCN expression is an important mechanism for tumor growth and for disease progression, specifically in MYCN-associated neuroblastoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3162.
Expanding Efforts to Prevent Chlamydial Infection
Authors: Walter E. Stamm
Journal: New England Journal of Medicine (1998)

Short of an effective vaccine, successful control of sexually transmitted Chlamydia trachomatis infections will require broadly based screening programs. This conclusion stems from several observations. First, chlamydial infections are highly prevalent, especially among adolescents and young adults, and are more widely distributed throughout all socioeconomic, racial, and ethnic groups than other bacterial sexually transmitted diseases.1 Second, most chlamydial infections in women and many in men do not cause symptoms. Third, once acquired, chlamydial infections may persist for months, resulting in a long period of potential transmission. And finally, these infections are treatable but if left untreated can cause pelvic inflammatory . . .
Kiss of Death
Authors: Brian B. Graham, Daniel R. Kaul, Sanjay Saint, William J. Janssen
Journal: New England Journal of Medicine (2009)

A 23-year-old South African man presented to an emergency department with a 2-day history of fever, mild dyspnea, headache, nausea, and myalgias. His symptoms had begun 5 days after he had traveled to Colorado to ski with friends.
Do enforced bicycle helmet laws improve public health?: Evidence is conflicting
Authors: Tony Raven
Journal: BMJ (2006)

EDITOR—Hagel et al cite six, mostly old, “independent” studies that support their views.1 Two are their own and another, after correction of an agreed mathematical error finds that helmets provide 186% protection—a clear case of major confounding.

Curiously they omit any reference to the many studies that don't support their views. For example, there is no reference to …
Childhood Obesity
Authors: Tessa L. Crume, Curtis S. Harrod
Journal: JAMA Pediatrics (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
An increased incidence of avoidable metabolic complications occur with inadequate clinical monitoring of patients receiving parenteral nutrition
Authors: N. Burch, J. Stewart, N. Smith
Journal: Gut (2011)

<h3>Introduction</h3> In June 2010, the National Confidential Enquiry into Patient Outcome and Death published ‘A Mixed Bag: an enquiry into the care of inpatients receiving parenteral nutrition9 (PN). This study found that only 19% of inpatients received care with respect to their PN that was considered good by the advisors peer reviewing the study. Additionally 39% of patients suffered metabolic complications, with 49% of these deemed avoidable. Only 32% of patients were deemed to have had adequate monitoring of their PN. This further analysis aimed to identify whether the incidence of metabolic complications correlated with inadequate review. <h3>Methods</h3> All patients in England and Wales who received PN between 1st January and 31st March 2008 were identified from pharmacy records. Two patients per consultant were identified. A clinical questionnaire was sent to be completed by the consultant for each patient, and then returned with a copy of the case notes. The questionnaires and case notes were then analysed by our Advisor group consisting of consultants, dieticians and pharmacists. <h3>Results</h3> In total 39% (249/634) of patients suffered metabolic complications, and of these 46% (98/211) were judged to have had inadequate monitoring. Avoidable metabolic complications were deemed to have occurred in 49% (81/164), with 62% (43/69) of these judged to have had inadequate monitoring. The commonest avoidable metabolic complications in both the adequately and inadequately monitored groups were hypophosphataemia, hypomagnesaemia and hyperglycaemia. All complications were almost twice as common in the inadequately monitored group. <h3>Conclusion</h3> These results show a marked increase in the likelihood of avoidable metabolic complications following PN administration in those not receiving adequate monitoring. In the most severe cases metabolic complications may result in the development of life-threatening cardiac arrhythmias, congestive cardiac failure, or sudden death. It is vital that those involved with inpatient PN management fully comprehend the magnitude of potential metabolic complications, and monitor patients appropriately. Early recognition and management of these complications results in reduced morbidity and mortality.1 As yet, the role of a specialist nutrition support team (NST) in the prevention of metabolic complications has remained unproven.2
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy
Authors: Patrick Marcellin, Karsten Wursthorn, Heiner Wedemeyer, Wan-Long Chuang, George Lau, Claudio Avila, Cheng-Yuan Peng, Edward Gane, Seng Gee Lim, Hugo Fainboim, Graham R. Foster, Rifaat Safadi, Mario Rizzetto, Michael Manns, Weibin Bao, Aldo Trylesinski, Nikolai Naoumov
Journal: Journal of Hepatology (2014)
Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers
Authors: Rifat Hasina, Nathan Mollberg, Ichiro Kawada, Karun Mutreja, Geetanjali Kanade, Soheil Yala, Mosmi Surati, Ren Liu, Xiuqing Li, Yue Zhou, Benjamin D. Ferguson, Vidya Nallasura, Kenneth S. Cohen, Elizabeth Hyjek, Jeffery Mueller, Rajani Kanteti, Essam El Hashani, Dorothy Kane, Yutaka Shimada, Mark W. Lingen, Aliya N. Husain, Mitchell C. Posner, Irving Waxman, Victoria M. Villaflor, Mark K. Ferguson, Lyuba Varticovski, Everett E. Vokes, Parkash Gill, Ravi Salgia
Journal: Cancer Research (2012)

Esophageal cancer incidence is increasing and has few treatment options. In studying receptor tyrosine kinases associated with esophageal cancers, we have identified EPHB4 to be robustly overexpressed in cell lines and primary tumor tissues. In total, 94 squamous cell carcinoma, 82 adenocarcinoma, 25 dysplasia, 13 Barrett esophagus, and 25 adjacent or unrelated normal esophageal tissues were evaluated by immunohistochemistry. EPHB4 expression was significantly higher in all the different histologic categories than in adjacent normal tissues. In 13 esophageal cancer cell lines, 3 of the 9 SCC cell lines and 2 of the 4 adenocarcinomas expressed very high levels of EPHB4. An increased gene copy number ranging from 4 to 20 copies was identified in a subset of the overexpressing patient samples and cell lines. We have developed a novel 4-nitroquinoline 1-oxide (4-NQO)-induced mouse model of esophageal cancer that recapitulates the EPHB4 expression in humans. A specific small-molecule inhibitor of EPHB4 decreased cell viability in a time- and dose-dependent manner in 3 of the 4 cell lines tested. The small-molecule inhibitor and an EPHB4 siRNA also decreased cell migration (12%-40% closure in treated vs. 60%-80% in untreated), with decreased phosphorylation of various tyrosyl-containing proteins, EphB4, and its downstream target p125FAK. Finally, in a xenograft tumor model, an EPHB4 inhibitor abrogated tumor growth by approximately 60% compared with untreated control. EphB4 is robustly expressed and potentially serves as a novel biomarker for targeted therapy in esophageal cancers.
Cost analysis of prophylaxis with antibiotics to prevent infected knee arthroplasty.
Authors: S. Bengtson, L. Borgquist, L. Lidgren
Journal: BMJ (1989)

A 72 year old woman presented with a five month history of pain of the mid-lumbar spine that had confined her to bed.Her other medical history was unremarkable.She experienced intense pain on turning in, or getting out of, bed.There was no spinal tenderness.Straight leg raising was full without neurological deficit.X Ray films showed generalised osteoporosis and a crush fracture of L3.A bone scan showed multiple sites of increased uptake throughout the spine.All blood tests, including liver function tests, gave normal results.Urinary calcium excretion was normal.Immunoelectrophoresis showed suppressed immuno- globulin concentrations: IgG 4-1 g/l, IgA <0 5 g/l, IgM <0 3 g/l.No serum paraprotein was ever identified.Immunoelectrophoresis of urine gave a positive result for Bence Jones protein on one occasion, but this was not confirmed in two further urine specimens.A trephine biopsy of the iliac crest showed that the marrow contained 30% plasma cells, including many abnormal forms.Immunohistochemical examination identified x light chains produced by plasma cells.Multiple myeloma was diagnosed, and she was treated with radiotherapy, melphalan, and prednisolone with satisfactory relief of pain.
Deficient urinary fibrinolysis in renal stone disease.
Authors: C A Charlton, C Osmond
Journal: BMJ (1986)

Broken necks in passengers in London taxi accidents Travelling by London taxi cab is considered to be safe.We present two cases of odontoid fracture as a result of taxi accidents. Case historiesCase 1-A 62 year old woman was a passenger in the back of a London taxi which collided with another car.She was thrown forward and hit her head on the partition between the passengers' and driver's compartments.She immediately experienced severe neck pain aggravated by movement.Examination showed occipital bruising, torticollis, and spasm of the neck muscles.No pharyngeal swelling or abnormal neurological signs were detected.Cervical radiographs showed an undisplaced fracture at the base of the odontoid peg.She was placed in a Plastazote collar, which eased her pain.The fracture healed spontaneously.Case 2-A 55 year old man was in the back of a cab when it was in a collision.He struck the left side ofhis head on the partition.Within two hours he developed severe neck pain.Examination showed torticollis, spasm ofthe neck muscles, but no abnormal neurological signs.He was placed in a conventional soft collar.His Minimall dipae odontoi frcue(ae2 _hw ycmue oorpy
Significance of High Soil Lead Concentrations for Childhood Lead Burdens
Authors: D. Barltrop, C. D. Strehlow, I. Thorton, J. S. Webb
Journal: Environmental Health Perspectives (1974)

The lead exposure of children and their mothers has been studied in two towns with mean soil lead contents of 900 and 400 ppm. No significant difference in blood or fecal lead contents was demonstrated between the two populations, but a small difference in hair lead content was shown. The blood lead content of children was greater than that of their mothers and was higher in the summer than in the spring samples. Children with pica for soil in the control area had increased lead content of blood and hair. Preliminary data for children and mothers from villages with mean soil lead contents of 500 ppm and 10,000 ppm are reported which show significant differences in blood and hair lead content within the normal range. The data suggest that soil lead content of 10,000 ppm may result in increased absorption of lead in children, but to a degree which is unlikely to be of biological significance.
Intracellular surface-enhanced Raman scattering probes based on TAT peptide-conjugated Au nanostars for distinguishing the differentiation of lung resident mesenchymal stem cells
Authors: Chaowen Shi, Xiaowei Cao, Xiang Chen, Zhaorui Sun, Zou Xiang, Hang Zhao, Weiping Qian, Xiaodong Han
Journal: Biomaterials (2015)
A CONSIDERATION OF THE NEUROSES OF STATUS LYMPHATICUS.
Authors: A. P. OHLMACHER
Journal: JAMA (1904)

Status lymphaticus, otherwise known as the lymphatic constitution, lymphatic diathesis, lymphatism, etc., is a so-called constitutional disorder, characterized by a persistence or hyperplasia of the thymus, general lymphadenoid hyperplasia, frequently associated with cardiac and arterial hypoplasia, and evidences of rachitis. The principal morbid anatomic features of status lymphaticus are a persistent or hypertrophie thymus, general or regional lymphadenoid hyperplasia including the lymphoid elements of the spleen, hypoplasia of the arteries and heart, very often with the osseous changes of rachitis. Occasional or accessory features are a thick skin, edema of the skin, lungs or brain, hypertrophie thyroid, hypertrophy of the brain, hypoplasia of the sexual organs, and lymphocytosis. A pronounced general active hyperemia is usually discovered in lymphatic individuals dying suddenly. That there is a close morbid anatomic association between status lymphaticus and rickets has been abundantly proven, particularly in the case of lymphatic infants. Still we are not at
Processus thérapeutique et deuil
Authors: Andre Haynal
Journal: Psychotherapy and Psychosomatics (1978)

Research Articles| February 16 2010 Processus thérapeutique et deuil Subject Area: Psychiatry and Psychology Andre Haynal Andre Haynal Faculté de Médecine, Genève Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1978) 29 (1-4): 174–176. https://doi.org/10.1159/000287122 Article history Published Online: February 16 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Andre Haynal; Processus thérapeutique et deuil. Psychother Psychosom 31 December 1978; 29 (1-4): 174–176. https://doi.org/10.1159/000287122 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search Article PDF first page preview Close Modal 1978Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
Sleight of Hand
Authors: Richard M. Berlin
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE ANTICOAGULANT AND ANTILYMPHOMA PROPERTIES OF ARSENIC AZOPROTEINS
Authors: J. D. Broome, John G. Kidd
Journal: The Journal of Experimental Medicine (1964)

Experiments here given show that 4-arsonophenylazoproteins form complexes with fibrinogen which are resistant to the enzymic action of thrombin, coagulation being thus inhibited; also that arsenic azoproteins combine strongly with polymerizing fibrin, the reaction leading uniquely to acceleration of the process. Ordinary arsenicals have little or no effect on the proliferation of Lymphoma 6C3HED cells in vivo. 4-Arsonophenylazoproteins, by contrast, are strongly inhibitory, and they arrest the process of mitosis in metaphase, as does colchicine. Considered together with the observations of the preceding paper, the findings suggest that 4-arsonophenylazoproteins may exert their anticoagulant and antilymphoma effects by similar or related means: in the former instance, by combining in vitro with fibrinogen and polymerizing fibrin, thus altering the clotting process as mentioned above; and in the latter instance by combining, perhaps in a similar way, with polymerizing proteins in the mitotic spindle of proliferating Lymphoma 6C3HED cells, thus arresting mitosis. Further implications of the findings are discussed.